Poor Pfizer. How will they spin this one? They are due to present data for a study known as IDEAL at the upcoming annual meeting of the American Heart Association. The trial involves almost 9,000 patients and compares the top dose of Lipitor to a lower dose of Zocor (soon to be generic simvastatin) marketed by Merck.
Have they missed getting a vital "p" value on the all-important primary end point?
Some analysts think so.
Fire up the spin machine......its going to be rough ride!
Source: Forbes
Update here:
http://www.forbes.com/sciencesandmedicine/2005/11/15/pfizer-lipitor-cholesterol-cx_mh_1115lipitor.html
1 comment:
Oh, this will be good.
Post a Comment